Skip Navigation

Vaccine Safety Bibliography - December 2012

1.   Global routine vaccination coverage,2011. Wkly Epidemiol Rec. 2012 Nov 2;87(44):432-5.

2.   Immunity wanes after vaccination against whooping cough. BMJ. 2012 Nov 28; 345:e8027.

3.   Ten valent vaccine prevents most invasive pneumococcal disease. BMJ. 2012 Nov 20; 345:e7826.

4.   The updated immunization recommendations for healthcare personnel. Home Healthc Nurse. 2012 Nov; 30(10):600-2.

5.   Abedi GR, Mutuc JD, Lawler J, Leroy ZC, Hudson JM, Blog DS, Schulte CR, Rausch-Phung E, Ogbuanu IU, Gallagher K, Kutty PK. Adverse events following a third dose of measles, mumps, and rubella vaccine in a mumps outbreak. Vaccine. 2012 Nov 19; 30(49):7052-8.

6.   Alexander F, Matheson M, Fry NK, Labram B, Gorringe AR. Antibody Responses to Individual Bordetella pertussis Fimbrial Antigen Fim2 or Fim3 following Immunization with the Five-Component Acellular Pertussis Vaccine or to Pertussis  Disease. Clin Vaccine Immunol. 2012 Nov; 19(11):1776-83.

7.   Allred NJ, Cover A, Zoldessy A, Smith P, Zhang F. School located vaccination clinics. J Ark Med Soc. 2012 Nov; 109(6):112.

8.   Amanna IJ, Hammarlund E, Lewis MW, Slifka MK. Impact of infection or vaccination on pre-existing serological memory. Hum Immunol. 2012 Nov; 73(11):1082-6.

9.   Ambrose CS, Wu X, Jones T, Mallory RM. The role of nasal IgA in children vaccinated with live attenuated influenza vaccine. Vaccine. 2012 Nov 6; 30(48):6794-801.

10.  Amdekar YK, Lalwani SK, Bavdekar A, Balasubramanian S, Chhatwal J, Bhat SR, Verghese VP, Tansey SP, Gadgil D, Jiang Q, Pride M, Emini EA, Gruber WC, Scott DA. Immunogenicity and Safety of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given with Routine Vaccines in India. Pediatr Infect Dis J. 2012 Nov 28. [Epub ahead of print].

11.  Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012 Nov 6; 30(48):6802-8.

12.  Ansakorpi H, Rusanen H, Rytky S, Färkkilä M. Lambert-Eaton myasthenic syndrome following H1N1-influenza vaccination: a case report. Acta Neurol Scand.  2012 Nov; 126(5):e25-8.

13.  Aoun B, Dourthe ME, Davourie Salandre A, Souberbielle JC, Ulinski T. Do vitamin D plasma levels impact vaccine response in children with idiopathic nephrotic syndrome? Pediatr Nephrol. 2012 Nov; 27(11):2161-2.

14.  Assaad U, El-Masri I, Porhomayon J, El-Solh AA. Pneumonia immunization in older adults: review of vaccine effectiveness and strategies. Clin Interv Aging.  2012; 7:453-61.

15.  Atkins KE, Shim E, Carroll S, Quilici S, Galvani AP. The cost-effectiveness of pentavalent rotavirus vaccination in England and Wales. Vaccine. 2012 Nov 6;30(48):6766-76.

16.  Azman AS, Luquero FJ, Rodrigues A, Palma PP, Grais RF, Banga CN, Grenfell BT, Lessler J. Urban cholera transmission hotspots and their implications for reactive vaccination: evidence from bissau city, Guinea bissau. PLoS Negl Trop Dis. 2012 Nov; 6(11):e1901.

17.  Bacon KM, Hotez PJ, Kruchten SD, Kamhawi S, Bottazzi ME, Valenzuela JG, Lee BY. The potential economic value of a cutaneous leishmaniasis vaccine in seven endemic countries in the Americas. Vaccine. 2012 Nov 20. [Epub ahead of print]PubMed PMID:

18.  Badertscher N, Morell S, Rosemann T, Tandjung R. General practitioners' experiences, attitudes, and opinions regarding the pneumococcal vaccination for adults: a qualitative study. Int J Gen Med. 2012;5:967-74.

19.  Bak R M, Türel O, Topachevskyi O. Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model. BMC Health Serv Res. 2012 Nov 9;12(1):386. [Epub ahead of print].

20.  Baker D, Niederhauser V. Immunizations: How do your patients score? Nurse Pract. 2012 Nov 10; 37(11):46-52.

21.  Ballestas TM, McEvoy SP. Rubella vaccination success in Australia: no time for complacency. Med J Aust. 2012 Nov 19; 197(10):551-2.

22.  Baratin D, Signore C, Thierry J, Caulin E, Vanhems P. Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010--2011. BMC Public Health. 2012 Nov 1;12(1):940. [Epub ahead of print].

23.  Barkoff AM, Gröndahl-Yli-Hannuksela K, Vuononvirta J, Mertsola J, Kallonen T, He Q. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection. Vaccine. 2012 Nov 6; 30(48):6897-902.

24.  Barnes MG, Ledford C, Hogan K. A "needling" problem: shoulder injury related  to vaccine administration. J Am Board Fam Med. 2012 Nov; 25(6):919-22.

25.  Barría MI, Garrido JL, Stein C, Scher E, Ge Y, Engel SM, Kraus TA, Banach D,  Moran TM. Localized Mucosal Response to Intranasal Live Attenuated Influenza Vaccine in Adults. J Infect Dis. 2012 Nov 21. [Epub ahead of print].

26.  Barskey AE, Schulte C, Rosen JB, Handschur EF, Rausch-Phung E, Doll MK, Cummings KP, Alleyne EO, High P, Lawler J, Apostolou A, Blog D, Zimmerman CM, Montana B, Harpaz R, Hickman CJ, Rota PA, Rota JS, Bellini WJ, Gallagher KM. Mumps outbreak in Orthodox Jewish communities in the United States. N Engl J Med. 2012 Nov; 367(18):1704-13.

27.  Bartsch SM, Lopman BA, Hall AJ, Parashar UD, Lee BY. The potential economic value of a human norovirus vaccine for the United States. Vaccine. 2012 Nov 19; 30(49):7097-104.

28.  Bednarczyk RA, Davis R, Ault K, Orenstein W, Omer SB. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics. 2012 Nov; 130(5):798-805. doi: 10.1542/peds.2012-1516.

29.  Bingham A, Gaspar F, Lancaster K, Conjera J, Collymore Y, Ba-Nguz A. Community perceptions of malaria and vaccines in two districts of Mozambique. Malar J. 2012 Nov 28; 11(1):394. [Epub ahead of print].

30.  Bologa M, Kamtchoua T, Hopfer R, Sheng X, Hicks B, Bixler G, Hou V, Pehlic V, Yuan T, Gurunathan S. Safety and immunogenicity of pneumococcal protein vaccine candidates: Monovalent choline-binding protein A (PcpA) vaccine and bivalent PcpA-pneumococcal histidine triad protein D vaccine. Vaccine. 2012 Dec 14; 30(52):7461-8.

31.  Borgers H, Meyts I, De Boeck K, Raes M, Sauer K, Proesmans M, Moens L, Jeurissen A, Flamaing J, Peetermans WE, Verhaegen J, Bossuyt X. Fold-increase in  antibody titer upon vaccination with pneumococcal unconjugated polysaccharide vaccine. Clin Immunol. 2012 Nov; 145(2):136-8.

32.  Brien S, Kwong JC, Charland KM, Verma AD, Brownstein JS, Buckeridge DL. Neighborhood Determinants of 2009 Pandemic A/H1N1 Influenza Vaccination in Montreal, Quebec, Canada. Am J Epidemiol. 2012 Nov 15; 176(10):897-908.

33.  Brookhart MA, Walker AM, Lu Y, Polakowski L, Li J, Paeglow C, Puenpatom T, Izurieta H, Daniel GW. Characterizing Vaccine-associated Risks Using Cubic Smoothing Splines. Am J Epidemiol. 2012 Nov 15; 176(10):949-57.

34.  Burchill MA, Tamburini BA, Pennock ND, White JT, Kurche JS, Kedl RM. T cell vaccinology: Exploring the known unknowns. Vaccine. 2012 Nov 6. [Epub ahead of print]

35.  Capone G, Lucchese G, Calabrò M, Kanduc D. West Nile virus diagnosis and vaccination: using unique viral peptide sequences to evoke specific immune responses. Immunopharmacol Immunotoxicol. 2013 Feb; 35(1):64-70.

36.  Centers for Medicare & Medicaid Services (CMS), HHS. Medicaid program; payments for services furnished by certain primary care physicians and charges for vaccine administration under the Vaccines for Children program. Final rule. Fed Regist. 2012 Nov 6;77(215):66669-701.

37.  Cerbino-Neto J, Santos AT, Gouvea MI, Pedro RS, Ramos GV, Guaraldo L, Werneck GL. Comparison of adverse events following immunization with pandemic influenza A (H1N1)pdm09 vaccine with or without adjuvant among health professionals in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz. 2012 Nov; 107(7):923-7.

38.  Ceyhan M, Celik M, Demir ET, Gurbuz V, Aycan AE, Unal S. Acquisition of meningococcal serogroup W-135 carriage in Turkish Hajees who had received quadrivalent meningococcal polysaccharide vaccine. Clin Vaccine Immunol. 2012 Nov 7. [Epub ahead of print].

39.  Chang S, O'Connor PM, Slade BA, Woo EJ. U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007. Vaccine. 2012 Nov 8. [Epub ahead of print].

40.  Chang YC, Huang N, Chen LS, Hsu SW, Chou YJ. Factors affecting repeated influenza vaccination among older people in Taiwan. Vaccine. 2012 Nov 7. [Epub ahead of print].

41.  Chen D, Zehrung D. Desirable attributes of vaccines for deployment in low-resource settings. J Pharm Sci. 2012 Nov 7. [Epub ahead of print].

42.  Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: Prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. Vaccine. 2012 Nov 19. [Epub ahead of print].

43.  Clark TA, Bobo N. CDC update on pertussis surveillance and Tdap vaccine recommendations. NASN Sch Nurse. 2012 Nov; 27(6):297-300.

44.  Cohen R, Levy C, Bechet S, Elbez A, Corrard F. [How pediatricians and GP consider the implementation of meningococal B vaccination in France?]. Arch Pediatr. 2012 Nov 15. [Epub ahead of print].

45.  Cuhaci Çakir B, Beyazova U, Kemaloğlu YK, Ozkan S, Gündüz B, Ozdek A. Effectiveness of pandemic influenza A/H1N1 vaccine for prevention of otitis media in children. Eur J Pediatr. 2012 Nov; 171(11):1667-71.

46.  Daily JP. Malaria Vaccine Trials - Beyond Efficacy End Points. N Engl J Med.  2012 Nov 9. [Epub ahead of print].

47.  Daniel M, Gautam S, Scrivener TA, Meller C, Levin B, Curotta J. What effect has pneumococcal vaccination had on acute mastoiditis? J Laryngol Otol. 2012 Nov  28:1-5. [Epub ahead of print].

48.  Danziger-Isakov L, Posfay-Barbe KM. Optimal approach to immunization in pediatric solid organ transplantation. Pediatr Transplant. 2012 Nov;16(7):680-3.  

49.  de Greeff SC, de Melker HE, Westerhof A, Schellekens JF, Mooi FR, van Boven M. Estimation of household transmission rates of pertussis and the effect of cocooning vaccination strategies on infant pertussis. Epidemiology. 2012 Nov; 23(6):852-60.

50.  Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R. Aflunov ®: a vaccine  tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin  Biol Ther. 2012 Nov 29. [Epub ahead of print].

51.  Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2012 Nov 26. [Epub ahead of print].

52.  Des Roches A, Paradis L, Gagnon R, Lemire C, Bégin P, Carr S, Chan ES, Paradis J, Frenette L, Ouakki M, Benoît M, De Serres G; PCIRN (Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network). Egg-allergic patients can be safely vaccinated against influenza. J Allergy Clin Immunol. 2012 Nov; 130(5):1213-1216.e1.

53.  Diazgranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and  its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials. Vaccine. 2012 Dec 17; 31(1):49-57.

54.  Diviani N, Camerini AL, Reinholz D, Galfetti A, Schulz PJ. Health literacy, health empowerment and health information search in the field of MMR vaccination: a cross-sectional study protocol. BMJ Open. 2012 Nov 19; 2(6).

55.  Dixon G, Clarke C. The effect of falsely balanced reporting of the autism-vaccine controversy on vaccine safety perceptions and behavioral intentions. Health Educ Res. 2012 Nov 27. [Epub ahead of print].

56.  Domínguez A. [What do we learn from outbreaks of vaccine-preventable diseases?]. Gac Sanit. 2012 Nov 29. [Epub ahead of print].

57.  Drees M, Tambourelli B, Denstman A, Zhang W, Zent R, McGraw P, Ehrenthal DB.  Sustained high influenza vaccination rates and decreased safety concerns among pregnant women during the 2010-2011 influenza season. Vaccine. 2012 Nov 10. [Epub ahead of print].

58.  Duclos P, Ortynsky S, Abeysinghe N, Cakmak N, Janusz CB, Jauregui B, Mihigo R, Mosina L, Sadr-Azodi N, Takashima Y, Dumolard L, Gacic-Dobo M. Monitoring of progress in the establishment and strengthening of national immunization technical advisory groups. Vaccine. 2012 Nov 26; 30(50):7147-52.

59.  Dórea JG. Breast-feeding and responses to infant vaccines: constitutional and environmental factors. Am J Perinatol. 2012 Nov;29(10):759-76.

60.  Edwards MS, Gonik B. Preventing the broad spectrum of perinatal morbidity and mortality through group B streptococcal vaccination. Vaccine. 2012 Nov 28. [Epub ahead of print].

61.  Egere U, Townend J, Roca A, Akinsanya A, Bojang A, Nsekpong D, Greenwood B, Adegbola RA, Hill PC. Indirect effect of 7-valent pneumococcal conjugate vaccine  on pneumococcal carriage in newborns in rural gambia: a randomised controlled trial. PLoS One. 2012;7(11):e49143.

62.  Erra EO, Askling HH, Yoksan S, Rombo L, Riutta J, Vene S, Lindquist L, Vapalahti O, Kantele A. Cross-Protective Capacity of Japanese Encephalitis (JE) Vaccines Against Circulating Heterologous JE Virus Genotypes. Clin Infect Dis. 2012 Nov 9. [Epub ahead of print].

63.  Esposito S, Marchisio P, Montinaro V, Bianchini S, Weverling GJ, Pariani E, Amendola A, Fabiano V, Pivetti V, Zanetti A, Zuccotti GV. The immunogenicity and  safety of a single 0.5mL dose of virosomal subunit influenza vaccine administered to unprimed children aged ≥6 to <36 months: Data from a randomized, Phase III study. Vaccine. 2012 Nov 19;30(49):7005-12.

64.  Farkas K, Terhes G, Deák J, Bálint A, Nagy F, Szepes Z, Wittmann T, Molnár T. [The efficiency of influenza vaccines in patients with inflammatory bowel disease on immunosuppressive therapy]. Orv Hetil. 2012 Nov 25;153(47):1870-4.

65.  Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions. Expert Rev Vaccines. 2012 Oct;11(10):1235-47.

66.  Feavers I, Griffiths E, Baca-Estrada M, Knezevic I, Zhou T. WHO/Health Canada meeting on regulatory considerations for evaluation and licensing of new meningococcal Group B vaccines, Ottawa, Canada, 3-4 October 2011. Biologicals. 2012 Nov;40(6):507-16.

67.  Flegel K. Health care workers must protect patients from influenza by taking  the annual vaccine. CMAJ. 2012 Nov 20;184(17):1873.

68.  Fowkes FJ, McGready R, Johnstone-Robertson S, Nosten F, Beeson JG. Antibody boosting and longevity following tetanus immunization during pregnancy. Clin Infect Dis. 2012 Nov 26. [Epub ahead of print].

69.  Fox CB, Barnes V L, Evers T, Chesko JD, Vedvick TS, Coler RN, Reed SG, Baldwin SL. Adjuvanted pandemic influenza vaccine: variation of emulsion components affects stability, antigen structure, and vaccine efficacy. Influenza  Other Respi Viruses. 2012 Nov 5. [Epub ahead of print].

70.  França IL, Ribeiro AC, Aikawa NE, Saad CG, Moraes JC, Goldstein-Schainberg C, Laurindo IM, Precioso AR, Ishida MA, Sartori AM, Silva CA, Bonfa E. TNF blockers  show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology (Oxford). 2012 Nov; 51(11):2091-8.

71.  Fu C, He Q, Xu J, Xie H, Ding P, Hu W, Dong Z, Liu X, Wang M. Effectiveness of the Lanzhou lamb rotavirus vaccine against gastroenteritis among children. Vaccine. 2012 Dec 17; 31(1):154-8.

72.  Furlow-Parmley C, Singleton JA, Bardenheier B, Bryan L. Combining estimates from two surveys: An example from monitoring 2009 influenza A (H1N1) pandemic vaccination. Stat Med. 2012 Nov 30; 31(27):3285-94.

73.  Gainforth HL, Cao W, Latimer-Cheung AE. Message Framing and Parents' Intentions to have their Children Vaccinated Against HPV. Public Health Nurs. 2012 Nov;29(6):542-52.

74.  Garcia CR, Manzi F, Tediosi F, Hoffman SL, James ER. Comparative cost models  of a liquid nitrogen vapor phase (LNVP) cold chain-distributed cryopreserved malaria vaccine vs. a conventional vaccine. Vaccine. 2012 Nov 9. [Epub ahead of print].

75.  Gasparini R, Amicizia D, Lai PL, Rossi S, Panatto D. Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V (®) and Fluad (®) ) in preventing hospitalization for influenza and pneumonia in the elderly: A matched  case-control study. Hum Vaccin Immunother. 2012 Nov 10;9(1). [Epub ahead of print].

76.  Gilchrist SA, Nanni A. Lessons learned in shaping vaccine markets in low-income countries: a review of the vaccine market segment supported by the GAVI Alliance. Health Policy Plan. 2012 Nov 22. [Epub ahead of print].

77.  Glenn GM, Smith G, Fries L, Raghunandan R, Lu H, Zhou B, Thomas DN, Hickman  SP, Kpamegan E, Boddapati S, Piedra PA. Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine. Vaccine. 2012 Nov 12. [Epub ahead of print].

78.  Goldstein E, Wallinga J, Lipsitch M. Vaccine allocation in a declining epidemic. J R Soc Interface. 2012 Nov 7; 9(76):2798-803.

79.  Grabenstein JD, O'Brien MA, Chen J. Cost-effectiveness of adult pneumococcal vaccination: Responding to: Weycker D, Sato R, Strutton D, Edelsberg J, Atwood M, Jackson LA. Public health and economic impact of 13-valent pneumococcal conjugate vaccine in US adults aged ≥50 years. Vaccine 2012; 30(August (36)):5437-44. Vaccine. 2012 Nov 12. [Epub ahead of print].

80.  Greene SK, Li L, Shay DK, Fry AM, Lee GM, Jacobsen SJ, Baxter R, Irving SA,  Jackson ML, Naleway AL, Nordin JD, Narwaney KJ, Lieu TA. Risk of adverse events following oseltamivir treatment in influenza outpatients, Vaccine Safety Datalink Project, 2007-2010. Pharmacoepidemiol Drug Saf. 2012 Nov 5. [Epub ahead of print].

81.  Greene SK, Shay DK, Yin R, McCarthy NL, Baxter R, Jackson ML, Jacobsen SJ, Nordin JD, Irving SA, Naleway AL, Glanz JM, Lieu TA. Patterns in influenza antiviral medication use before and during the 2009 H1N1 pandemic, Vaccine Safety Datalink Project, 2000-2010. Influenza Other Respi Viruses. 2012 Nov;6(6):e143-e151.

82.  Groom AV, Santibanez TA, Bryan RT. Vaccination coverage among American Indian and alaska native children, 2006-2010. Pediatrics. 2012 Dec; 130(6):e1592-9.

83.  Grose C, Juhn Y. COMMENTARY: Significantly Less Anti-gC Antibody Detectable  in Sera Collected After Varicella Vaccination Than After the Disease Varicella. Pediatr Infect Dis J. 2012 Nov; 31(11):1153-4.

84.  Guiso N. Specific biological diagnoses are needed to determine the durability of pertussis vaccine-induced immunity. Clin Infect Dis. 2012 Nov; 55(10):1433-4.

85.  Gulland A. Malaria vaccine trial shows lower efficacy in younger than in older infants. BMJ. 2012 Nov 13; 345:e7665.

86.  Gunatheesan S, Ferguson J, Moosa Y. Pityriasis lichenoides et varioliformis  acuta: A rare association with the measles, mumps and rubella vaccine. Australas  J Dermatol. 2012 Nov; 53(4):e76-8.

87.  Guzman-Cottrill JA, Phillipi CA, Dolan SA, Nyquist AC, Win A, Siegel J. Free vaccine programs to cocoon high-risk infants and children against influenza and pertussis. Am J Infect Control. 2012 Nov;40(9):872-6.

88.  Haile ZT, Chertok IR, Teweldeberhan AK. Determinants of Utilization of Sufficient Tetanus Toxoid Immunization During Pregnancy: Evidence from the Kenya  Demographic and Health Survey, 2008-2009. J Community Health. 2012 Nov 18. [Epub  ahead of print].

89.  Halloran ME, Hudgens MG. Comparing bounds for vaccine effects on infectiousness. Epidemiology. 2012 Nov; 23(6):931-2.

90.  Halstead SB. Dengue vaccine development: a 75% solution? Lancet. 2012 Nov 3; 380(9853):1535-6.

91.  Hawken J, Troy SB. Adjuvants and inactivated polio vaccine: A systematic review. Vaccine. 2012 Nov 19; 30(49):6971-9.

92.  Hawken S, Wilson KR. The self-controlled case series method for evaluating safety of vaccines. Med J Aust. 2012 Nov 19; 197(10):578-9.

93.  Hawken S, Manuel DG, Deeks SL, Kwong JC, Crowcroft NS, Wilson K. Underestimating the safety benefits of a new vaccine: the impact of acellular pertussis vaccine versus whole-cell pertussis vaccine on health services utilization. Am J Epidemiol. 2012 Dec 1; 176(11):1035-42.

94.  Hedden EM, Jessop AB, Field RI. Childhood immunization reporting laws in the United States: Current status. Vaccine. 2012 Nov 19; 30(49):7059-66.

95.  Hernandez-Bou S, Garcia-Garcia JJ, Gene A, Esteva C, Del Amo E, Muñoz-Almagro C. Pneumococcal carriage in children attending a hospital outpatient clinic in the era of pneumococcal conjugate vaccines in Barcelona. Diagn Microbiol Infect Dis. 2012 Nov; 74(3):258-62.

96.  Hernández-García I, Domínguez B, González R. Influenza vaccination rates and determinants among Spanish medical students. Vaccine. 2012 Dec 17; 31(1):1-2.

97.  Hinge M, Ingels HA, Slotved HC, Mølle I. Serologic response to a 23-valent pneumococcal vaccine administered prior to autologous stem cell transplantation in patients with multiple myeloma. APMIS. 2012 Nov; 120(11):935-40.

98.  Hirve S, Bavdekar A, Juvekar S, Benn CS, Nielsen J, Aaby P. Non-specific and sex-differential effects of vaccinations on child survival in rural western India. Vaccine. 2012 Nov 26;30(50):7300-8.

99.  Holmgren J. A case for control of cholera in Africa by vaccination. Lancet Infect Dis. 2012 Nov; 12(11):818-9.

100. Hornshøj L, Benn CS, Fernandes M, Rodrigues A, Aaby P, Fisker AB. Vaccination coverage and out-of-sequence vaccinations in rural Guinea-Bissau: an  observational cohort study. BMJ Open. 2012 Nov 19; 2(6).

101. Huppertz HI, Bartmann P, Heininger U, Fingerle V, Kinet M, Klein R, Korenke  GC, Nentwich HJ. Rational diagnostic strategies for Lyme borreliosis in children  and adolescents: recommendations by the Committee for Infectious Diseases and Vaccinations of the German Academy for Pediatrics and Adolescent Health. Eur J Pediatr. 2012 Nov; 171(11):1619-24.

102. Hwang CW Jr, Steigleman WA, Saucedo-Sanchez E, Tuli SS. Reactivation of Herpes Zoster Keratitis in an Adult After Varicella Zoster Vaccination. Cornea. 2012 Nov 26. [Epub ahead of print]

103. Iacobucci G. First meningitis B vaccine could be available in UK next year.  BMJ. 2012 Nov 20; 345:e7867.

104. Iwamoto M, Homma S, Onishi S, Kamata Y, Nagatani K, Yamagata Z, Minota S. Low level of seroconversion after a novel influenza A/H1N1/2009 vaccination in Japanese patients with rheumatoid arthritis in the 2009 season. Rheumatol Int. 2012 Nov; 32(11):3691-4.

105. Jenke AC, Klein S, Baiker A, Wirth S, Sander M, Noelting C, Boecher O, Vizoso-Pinto MG. Serologic Analysis of the IgG Antibody Response in Children With Varicella Zoster Virus Wild-type Infection and Vaccination. Pediatr Infect Dis J. 2012 Nov;31(11):1148-52.

106. John TJ, Vashishtha VM. Polio vaccination in Pakistan. Lancet. 2012 Nov 10;380(9854):1645; author reply 1645-6.

107. Justino MC, Araújo EC, van Doorn LJ, Oliveira CS, Gabbay YB, Mascarenhas JD, Miranda YS, Guerra Sde F, Silva VB, Linhares AC. Oral live attenuated human rotavirus vaccine (RotarixTM) offers sustained high protection against severe G9P[8] rotavirus gastroenteritis during the first two years of life in Brazilian  children. Mem Inst Oswaldo Cruz. 2012 Nov;107(7):846-53.

108. Kakoulidou M, Ingelman-Sundberg H, Johansson E, Cagigi A, Farouk SE, Nilsson A, Johansen K. Kinetics of antibody and memory B cell responses after MMR immunization in children and young adults. Vaccine. 2012 Nov 19. [Epub ahead of print].

109. Kamphuis E, Hanschmann KM, Meyer H, Göpfert C, Krämer B, Cussler K. Potency  estimation of vaccine batches remains unaffected by anesthesia for intracerebral  injection. Biologicals. 2012 Nov;40(6):451-5.

110. Kamtchoua T, Bologa M, Hopfer R, Neveu D, Hu B, Sheng X, Corde N, Pouzet C,  Zimmermann G, Gurunathan S. Safety and immunogenicity of the pneumococcal pneumolysin derivative PlyD1 in a single-antigen protein vaccine candidate in adults. Vaccine. 2012 Nov 12. [Epub ahead of print]

111. Kawai K, Oʼbrien MA, Conway JH, Marshall GS, Kuter BJ. Factors Associated with Receipt of Two Doses of Varicella Vaccine among Adolescents in the United States. Pediatr Infect Dis J. 2012 Nov 28. [Epub ahead of print].

112. Kersh GJ, Fitzpatrick KA, Self JS, Biggerstaff BJ, Massung RF. Long-term immune responses to Coxiella burnetii after vaccination. Clin Vaccine Immunol. 2012 Nov 28. [Epub ahead of print].

113. Khatib AM, Ali M, von Seidlein L, Kim DR, Hashim R, Reyburn R, Ley B, Thriemer K, Enwere G, Hutubessy R, Aguado MT, Kieny MP, Lopez AL, Wierzba TF, Ali SM, Saleh AA, Mukhopadhyay AK, Clemens J, Jiddawi MS, Deen J. Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study. Lancet Infect Dis. 2012 Nov;12(11):837-44.

114. Khowaja AR, Sheikh S, Saleem AF, Zaidi AK. Parental Awareness and Coverage of Mass Measles Vaccination Drive 2011: Cross-Sectional Survey in the Metropolitan City of Karachi, Pakistan. Asia Pac J Public Health. 2012 Nov 18. [Epub ahead of print].

115. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012 Nov; 64(14):1547-68.

116. Klein S, Schöneberg I, Krause G. [The historical development of immunization in Germany : From compulsory smallpox vaccination to a National Action Plan on Immunization]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2012 Nov; 55(11-12):1512-23.  

117. Knezevic I, Griffiths E, Petricciani J, Bramley D. The WHO network of collaborating centres on standardization and regulatory evaluation of vaccines. Biologicals. 2012 Nov;40(6):499-506.

118. Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning Antibody Levels and Avidity: Implications for MMR Vaccine-Induced Protection. J Infect Dis. 2012  Nov;206(10):1542-8.

119. Korošec P, Petrovec M, Lainščscak M, Meško P, Silar M, Košnik M. High Non-Specific T Lymphocyte Response to the Adjuvanted H1N1 Vaccine in Comparison with the H1N1/H3N2/B-Brisbane Vaccine without Adjuvant. Scand J Immunol. 2012 Nov; 76(5):497-504.

120. Kristiansen PA, Diomandé F, Ba AK, Sanou I, Ouédraogo AS, Ouédraogo R, Sangaré L, Kandolo D, Aké F, Saga IM, Clark TA, Misegades L, Martin SW, Thomas JD, Tiendrebeogo SR, Hassan-King M, Djingarey MH, Messonnier NE, Préziosi MP, Laforce FM, Caugant DA. Impact of the Serogroup A Meningococcal Conjugate Vaccine, MenAfriVac, on Carriage and Herd Immunity. Clin Infect Dis. 2012 Nov 19. [Epub ahead of print].

121. Kuehn BM. ACIP: Give pertussis vaccine during every pregnancy. JAMA. 2012 Nov 21; 308(19):1960.

122. Kulkarni PS, Manjunath K, Agarkhedkar S; Group of SII IIV Studies. Safety and immunogenicity of an adjuvanted whole virion, inactivated A (H1N1) 2009 influenza vaccine in young and elderly adults, and children. Vaccine. 2012 Dec 17; 31(1):20-2.

123. Ladhani SN, Andrews NJ, Waight P, Borrow R, Slack MP, Miller E. Impact of the 7-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease in Infants Younger Than 90 Days in England and Wales. Clin Infect Dis. 2012 Nov 30.  [Epub ahead of print].

124. Larson H, Brocard Paterson P, Erondu N. The globalization of risk and risk perception: why we need a new model of risk communication for vaccines. Drug Saf. 2012 Nov 1;35(11):1053-9.

125. Lau D, Hu J, Majumdar SR, Storie DA, Rees SE, Johnson JA. Interventions to improve influenza and pneumococcal vaccination rates among community-dwelling adults: a systematic review and meta-analysis. Ann Fam Med. 2012 Nov;10(6):538-46.

126. Ledgerwood JE, Hu Z, Gordon IJ, Yamshchikov G, Enama ME, Plummer S, Bailer R, Pearce MB, Tumpey TM, Koup RA, Mascola JR, Nabel GJ, Graham BS; VRC 304 and VRC 305 Study Teams. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol. 2012 Nov; 19(11):1792-7.

127. Levine H, Ankol OE, Rozhavski V, Davidovitch N, Aboudy Y, Zarka S, Balicer RD. Rubella seroprevalence in the first birth cohort reaching fertility age after 20 years of two dose universal vaccination policy in Israel. Vaccine. 2012 Nov 26;30(50):7260-4.

128. Li F, Wang Q, Zhang L, Su H, Zhang J, Wang T, Huang D, Wu J, Yan Y, Fan D. The risk factors of transmission after the implementation of the routine immunization among children exposed to HBV infected mothers in a developing area  in northwest China. Vaccine. 2012 Nov 19;30(49):7118-22.

129. Li YP, Li W, Liang XF, Liu Y, Huang XC, Li CG, Li RC, Wang JZ, Wang HQ, Yin  WD. Immunogenicity and safety of a 2009 pandemic influenza A (H1N1) monovalent vaccine in Chinese infants aged 6-35 months: a randomized, double-blind, controlled phase I clinical trial. Influenza Other Respi Viruses. 2012 Nov 8. [Epub ahead of print].

130. Lievano F, Galea SA, Thornton M, Wiedmann RT, Manoff SB, Tran TN, Amin MA, Seminack MM, Vagie KA, Dana A, Plotkin SA. Measles, mumps, and rubella virus vaccine (M-M-RTMII): A review of 32 years of clinical and postmarketing experience. Vaccine. 2012 Nov 6;30(48):6918-26.

131. Liu N, Yen C, Fang ZY, Tate JE, Jiang B, Parashar UD, Zeng G, Duan ZJ. Projected health impact and cost-effectiveness of rotavirus vaccination among children <5 years of age in China. Vaccine. 2012 Nov 6;30(48):6940-5.

132. Locht C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol. 2012 Nov;66(2):121-33.

133. Loughlin AM, Marchant CD, Adams W, Barnett E, Baxter R, Black S, Casey C, Dekker C, Edwards KM, Klein J, Klein NP, Larussa P, Sparks R, Jakob K. Causality  assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Nov 26; 30(50):7253-9.

134. Low N, Scott P, Henao Restrepo AM. Comparing pneumococcal conjugate vaccine  schedules in infancy. Vaccine. 2012 Nov 26; 30(50):7145.

135. Luke JL, McDonald L, Jude V, Chan KW, Cuellar NG. Clinical Practice Implications of Immunizations After Pediatric Bone Marrow Transplant: A Literature Review. J Pediatr Oncol Nurs. 2012 Nov 16. [Epub ahead of print].

136. Madan RP, Herold BC. Mounting evidence suggests safety and efficacy of immunizations posttransplantation. Am J Transplant. 2012 Nov; 12(11):2871-2.

137. Mahamud A, Wiseman R, Grytdal S, Basham C, Asghar J, Dang T, Leung J, Lopez  A, Schmid DS, Bialek SR. Challenges in confirming a varicella outbreak in the two-dose vaccine era. Vaccine. 2012 Nov 6;30(48):6935-9.

138. Mamma M, Spandidos DA. Economic evaluation of the vaccination program against seasonal and pandemic A/H1N1 influenza among customs officers in Greece.  Health Policy. 2012 Nov 26. [Epub ahead of print].

139. Marchetti E, Mazarin-Diop V, Chaumont J, Martellet L, Makadi MF, Viviani S,  Kulkarni PS, Preziosi MP. Conducting vaccine clinical trials in sub-Saharan Africa: Operational challenges and lessons learned from the Meningitis Vaccine Project. Vaccine. 2012 Nov 6;30(48):6859-63. 

140. Martin SD, Girouard T. The updated immunization recommendations for healthcare personnel. Home Healthc Nurse. 2012 Nov;30(10):596-600.

141. Mastelic B, Lewis DJ, Golding H, Gust I, Sheets R, Lambert PH. Potential use of inflammation and early immunological event biomarkers in assessing vaccine safety. Biologicals. 2012 Nov 27. [Epub ahead of print].

142. McCormick EV, Durfee J, Vogt TM, Daley MF, Hambidge SJ, Shlay J. Physician attitudes regarding school-located vaccinations. Pediatrics. 2012 Nov;130(5):887-96.

143. McIntyre PB, O'Brien KL, Greenwood B, van de Beek D. Effect of vaccines on bacterial meningitis worldwide. Lancet. 2012 Nov 10;380(9854):1703-11.

144. Megerlin F. [Vaccination and French community pharmacists: From innovative actions to innovative organisations?]. Ann Pharm Fr. 2012 Nov;70(6):323-32.

145. Menni F, Chiarelli G, Sabatini C, Principi N, Esposito S. Vaccination in children with inborn errors of metabolism. Vaccine. 2012 Nov 26; 30(50):7161-4.

146. Miles M, Ryman TK, Dietz V, Zell E, Luman ET. Validity of vaccination cards  and parental recall to estimate vaccination coverage: A systematic review of the  literature. Vaccine. 2012 Nov 26. [Epub ahead of print].

147. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P. 1976  and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies  in Humans. J Infect Dis. 2012 Nov 16. [Epub ahead of print].

148. Misegades LK, Winter K, Harriman K, Talarico J, Messonnier NE, Clark TA, Martin SW. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA. 2012 Nov 28; 308(20):2126-32.

149. Misegades LK, Martin SW, Messonnier NE, Clark TA. Estimating the effectiveness of acellular pertussis vaccines. Clin Infect Dis. 2012 Nov; 55(10):1432-3.

150. Moreau R, Lepage H, Blanchet F, Megerlin F. [Community pharmacist and vaccination: Actuality and opportunity]. Ann Pharm Fr. 2012 Nov; 70(6):309-14.

151. Morin MP, Quach C, Fortin E, Chédeville G. Vaccination coverage in children  with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatology (Oxford). 2012 Nov; 51(11):2046-50.

152. Muegge S. Protecting Refrigerated Vaccines with Water Bottles: An Evidence-Based Strategy. Am J Nurs. 2012 Nov; 112(11):61-69.

153. Mueller JE. Conjugate vaccine introduction in the African meningitis belt: meeting surveillance objectives. Trop Med Int Health. 2012 Nov 2. [Epub ahead of print].

154. Muhammad RD, Oza-Frank R, Zell E, Link-Gelles R, Narayan KM, Schaffner W, Thomas A, Lexau C, Bennett NM, Farley MM, Harrison LH, Reingold A, Hadler J, Beall B, Klugman KP, Moore MR. Epidemiology of Invasive Pneumococcal Disease among High-Risk Adults since Introduction of Pneumococcal Conjugate Vaccine for Children. Clin Infect Dis. 2012 Nov 15. [Epub ahead of print]

155. Munoz FM, Ferrieri P. Group B streptococcus vaccination in pregnancy: Moving toward a global maternal immunization program. Vaccine. 2012 Nov 21. [Epub ahead of print].

156. Myers MG. Vaccination to prevent varicella. Vaccine. 2012 Nov 16. [Epub ahead of print].

157. Nace DA, Handler SM, Hoffman EL, Perera S. Impact of the Raising Immunizations Safely and Effectively (RISE) Program on Healthcare Worker Influenza Immunization Rates in Long Term Care Settings. J Am Med Dir Assoc. 2012 Nov; 13(9):806-10.

158. Nan X, Madden K. HPV vaccine information in the blogosphere: how positive and negative blogs influence vaccine-related risk perceptions, attitudes, and behavioral intentions. Health Commun. 2012 Nov; 27(8):829-36.

159. Nayak JL, Fitzgerald TF, Richards KA, Yang H, Treanor JJ, Sant AJ. CD4 T-cell expansion predicts neutralizing antibody responses to monovalent inactivated pandemic H1N1 influenza vaccine. J Infect Dis. 2012 Nov 12. [Epub ahead of print].

160. Nevin RL. Confounding and bias in studies of DMSS vaccination data. Vaccine. 2012 Nov 26; 30(50):7146.

161. Nguyen S, Huleux T, Choisy P, Senneville E, Ajana F. Vaccinal issues between Belgian and French travelers. Med Mal Infect. 2012 Nov; 42(11):545-52.

162. Nicolas P. Meningococcal meningitis epidemics in sub-Saharan Africa and the  meningococcal A conjugate vaccine. Med Sante Trop. 2012 Nov 27. [Epub ahead of print].

163. Niedzielski A, Korona-Głowniak I, Malm A, Mielnik-Niedzielska G. Distribution of vaccine serotypes among Streptococcus pneumoniae colonizing the upper respiratory tract in healthy pre school children in south-east Poland. Otolaryngol Pol. 2012 Nov;66(6):403-6.

164. Nikula A, Puukka P, Leino-Kilpi H. Vaccination competence of graduating public health nurse students and nurses. Nurse Educ Today. 2012 Nov; 32(8):850-6.  

165. Nowalk MP, Clinch CR, Tarn DM, Chang T, Ncube CN, Troy JA, Zimmerman RK. Shots by STFM: Value of Immunization Software to Family Medicine Residency Directors: A CERA Study. Fam Med. 2012 Nov; 44(10):716-8.

166. O'Keefe DJ, Nan X. The relative persuasiveness of gain- and loss-framed messages for promoting vaccination: a meta-analytic review. Health Commun. 2012 Nov; 27(8):776-83.

167. O'Leary ST, Suh CA, Marin M; the Vaccine Policy Collaborative Initiative. Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: What do primary care physicians think? Vaccine. 2012 Nov 6;30(48):6731-6733.

168. O'Mahony JF. Re: Cost-effectiveness of pertussis booster vaccination in the  Netherlands. Vaccine. 2012 Nov 26; 30(50):7141.

169. Ogbuanu IU, Kutty PK, Hudson JM, Blog D, Abedi GR, Goodell S, Lawler J, McLean HQ, Pollock L, Rausch-Phung E, Schulte C, Valure B, Armstrong GL, Gallagher K. Impact of a third dose of measles-mumps-rubella vaccine on a mumps outbreak. Pediatrics. 2012 Dec; 130(6):e1567-74.

170. Oncel S, Alvur M. How reliable is the Internet for caregivers on their decision to vaccinate their child against influenza? Results from googling in two languages. Eur J Pediatr. 2012 Nov 10. [Epub ahead of print].

171. Ortiz JR, Neuzil KM, Ahonkhai VI, Gellin BG, Salisbury DM, Read JS, Adegbola RA, Abramson JS. Translating vaccine policy into action: A report from the Bill & Melinda Gates Foundation Consultation on the prevention of maternal and early infant influenza in resource-limited settings. Vaccine. 2012 Nov 26; 30(50):7134-40.

172. Ovsyannikova IG, Haralambieva IH, Kennedy RB, Pankratz VS, Vierkant RA, Jacobson RM, Poland GA. Impact of cytokine and cytokine receptor gene polymorphisms on cellular immunity after smallpox vaccination. Gene. 2012 Nov 15; 510(1):59-65. 

173. Ozawa S, Mirelman A, Stack ML, Walker DG, Levine OS. Cost-effectiveness and  economic benefits of vaccines in low- and middle-income countries: A systematic review. Vaccine. 2012 Dec 17; 31(1):96-108.

174. Pandolfi E, Marino MG, Carloni E, Romano M, Gesualdo F, Borgia P, Carloni R, Guarino A, Giannattasio A, Tozzi AE. The effect of physician's recommendation on  seasonal influenza immunization in children with chronic diseases. BMC Public Health. 2012 Nov 15; 12(1):984. [Epub ahead of print].

175. Paris B, Arahood T, Asche C, Amundson G. Voluntary reporting of health care  personnel seasonal influenza vaccination rates and the impact of universal policies in Illinois hospitals. Vaccine. 2012 Nov 20. [Epub ahead of print].

176. Partridge J, Kieny MP. Global production capacity of seasonal influenza vaccine in 2011. Vaccine. 2012 Nov 10. [Epub ahead of print].

177. Paternina-Caicedo A, De la Hoz-Restrepo F, Gamboa-Garay O, Castañeda-Orjuela C, Velandia-González M, Alvis-Guzmán N. How cost effective is universal varicella vaccination in developing countries? A case-study from Colombia. Vaccine. 2012 Nov 19. [Epub ahead of print].

178. Patrzalek M, Gorynski P, Albrecht P. Indirect population impact of universal PCV7 vaccination of children in a 2 + 1 schedule on the incidence of pneumonia morbidity in Kielce, Poland. Eur J Clin Microbiol Infect Dis. 2012 Nov;31(11):3023-8.

179. Peck JL, Stanton M, Reynolds GE. Smartphone Preventive Health Care: Parental Use of an Immunization Reminder System. J Pediatr Health Care. 2012 Nov 27. [Epub ahead of print]

180. Perring S, Jones E. Assessment of changes in cardiac autonomic tone resulting from inflammatory response to the influenza vaccination. Clin Physiol Funct Imaging. 2012 Nov;32(6):437-44.

181. Petráš M, Sýkora T, Andrýs C, Drahošová M. Post-vaccination anti-human papillomavirus antibody seroprevalence among Czech teenaged girls and women. Int  J Gynaecol Obstet. 2012 Nov;119(2):178-81.

182. Phillips CJ, Woolpert T, Sevick C, Faix D, Blair PJ, Crum-Cianflone NF. Comparison of the Effectiveness of Trivalent Inactivated Influenza Vaccine and Live, Attenuated Influenza Vaccine in Preventing Influenza-Like Illness Among US  Military Service Members, 2006-2009. Clin Infect Dis. 2012 Nov 26. [Epub ahead of print].

183. Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and Immunogenicity of a Quadrivalent Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Infants and Toddlers: Three Multicenter Phase III Studies. Pediatr Infect Dis J. 2012 Nov;31(11):1173-83.

184. Poland GA. Pertussis outbreaks and pertussis vaccines: New insights, new concerns, new recommendations? Vaccine. 2012 Nov 19; 30(49):6957-9.

185. Poole T, Goodyear-Smith F, Petousis-Harris H, Desmond N, Exeter D, Pointon L, Jayasinha R. Human papillomavirus vaccination in Auckland: Reducing ethnic and socioeconomic inequities. Vaccine. 2012 Dec 17; 31(1):84-8.

186. Porat N, Benisty R, Trefler R, Givon-Lavi N, Dagan R. Clonal Distribution of Common Pneumococcal Serotypes Not Included in the 7-Valent Conjugate Vaccine (PCV7): Marked Differences between Two Ethnic Populations in Southern Israel. J Clin Microbiol. 2012 Nov; 50(11):3472-7.

187. Posfay-Barbe KM, Pittet LF, Sottas C, Grillet S, Wildhaber BE, Rodriguez M,  Kaiser L, Belli DC, McLin VA, Siegrist CA. Varicella-Zoster Immunization in Pediatric Liver Transplant Recipients: Safe and Immunogenic. Am J Transplant. 2012 Nov;12(11):2974-2985.

188. Prabowo SA, Gröschel MI, Schmidt ED, Skrahina A, Mihaescu T, Hastürk S, Mitrofanov R, Pimkina E, Visontai I, de Jong B, Stanford JL, Cardona PJ, Kaufmann SH, van der Werf TS. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med Microbiol Immunol. 2012 Nov 10. [Epub ahead of print].

189. Prelog M, Almanzar G, Rieber N, Ottensmeier B, Zlamy M, Liese J. Differences of IgG antibody avidity after an acellular pertussis (aP) booster in adolescents  after a whole cell (wcP) or aP primary vaccination. Vaccine. 2012 Nov 8. 10. [Epub ahead of print].    

190. Prelog M. Differential Approaches for Vaccination from Childhood to Old Age. Gerontology. 2012 Nov 24. [Epub ahead of print].

191. Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine. 2012 Nov 12. [Epub ahead of print].

192. Renner B, Reuter T. Predicting vaccination using numerical and affective risk perceptions: The case of A/H1N1 influenza. Vaccine. 2012 Nov 19; 30(49):7019-26.

193. Richie TL, Villasante EF. Use of Adenovirus Serotype 5 Vaccine Vectors in Seropositive, Uncircumcised Men: Safety Lessons from the Step Trial. J Infect Dis. 2012 Nov 29. [Epub ahead of print].

194. Richie TL, Charoenvit Y, Wang R, Epstein JE, Hedstrom RC, Kumar S, Luke TC,  Freilich DA, Aguiar JC, Sacci JB, Sedegah M, Nosek RA, De La Vega P, Berzins MP,  Majam VF, Abot EN, Ganeshan H, Richie NO, Banania JG, Baraceros MF, Geter TG, Mere R, Bebris L, Limbach K, Hickey BW, Lanar DE, Ng J, Shi M, Hobart PM, Norman  JA, Soisson LA, Hollingdale MR, Rogers WO, Doolan DL, Hoffman SL. Clinical trial  in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA. Hum Vaccin Immunother. 2012 Nov 1;8(11). [Epub ahead of print].   

195. Ridda I, Yin JK, King C, Raina Macintyre C, McIntyre P. The importance of pertussis in older adults: A growing case for reviewing vaccination strategy in the elderly. Vaccine. 2012 Nov 6; 30(48):6745-52.

196. Robberstad B, Akselsen PE, Kværner KJ, Berstad AK. Response to "Reply to: Economic evaluation of second generation pneumococcal conjugate vaccines in Norway". Vaccine. 2012 Nov 28. [Epub ahead of print].

197. Rodas JR, Lau CH, Zhang ZZ, Griffiths SM, Luk WC, Kim JH. Exploring predictors influencing intended and actual acceptability of the A/H1N1 pandemic vaccine: A cohort study of university students in Hong Kong. Public Health. 2012  Nov 6. [Epub ahead of print].

198. Rostami K, Nejad MR. Vaccinations in Celiac Disease. J Pediatr Gastroenterol Nutr. 2012 Nov 3. [Epub ahead of print].

199. Rowland R, Pathan AA, Satti I, Poulton ID, Matsumiya MM, Whittaker M, Minassian AM, O'Hara GA, Hamill M, Scott JT, Harris SA, Poyntz HC, Bateman C, Meyer J, Williams N, Gilbert SC, Lawrie AM, Hill AV, McShane H. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: A phase I clinical trial. Hum Vaccin Immunother. 2012 Nov 10; 9(1). [Epub ahead of print].

200. Rozenbaum MH, De Cao E, Postma MJ. Cost-effectiveness of pertussis booster vaccination in the Netherlands. Vaccine. 2012 Nov 26; 30(50):7327-31.

201. Rozhnova G, Nunes A. Modelling the long-term dynamics of pre-vaccination pertussis. J R Soc Interface. 2012 Nov 7; 9(76):2959-70.

202. Rueckert C, Guzmán CA. Vaccines: from empirical development to rational design. PLoS Pathog. 2012 Nov; 8(11):e1003001.

203. Rüger G, Gabutti G, Rümke H, Rombo L, Bernaola E, Diez-Domingo J, Martinon-Torres F, Høgh B, Konstantopoulos A, Fiquet A, Thomas S, Eymin C, Baudin M. Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine Manufactured With Recombinant Human Albumin. Pediatr Infect Dis J. 2012 Nov; 31(11):1166-1172.

204. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet. 2012 Nov 3; 380(9853):1559-67.

205. Sagar V, Bergmann R, Nerlich A, McMillan DJ, Nitsche Schmitz DP, Chhatwal GS. Variability in the Distribution of Genes Encoding Virulence Factors and Putative Extracellular Proteins of Streptococcus pyogenes in India, a Region with High Streptococcal Disease Burden, and Implication for Development of a Regional  Multisubunit Vaccine. Clin Vaccine Immunol. 2012 Nov; 19(11):1818-25.

206. Saha A, Chowdhury MI, Nazim M, Alam MM, Ahmed T, Hossain MB, Hore SK, Sultana GN, Svennerholm AM, Qadri F. Vaccine specific immune response to an inactivated oral cholera vaccine and EPI vaccines in a high and low arsenic area  in Bangladeshi children. Vaccine. 2012 Nov 28. [Epub ahead of print].

207. Salmon D, Yih WK, Lee G, Rosofsky R, Brown J, Vannice K, Tokars J, Roddy J,  Ball R, Gellin B, Lurie N, Koh H, Platt R, Lieu T; the PRISM Program Group. Success Of Program Linking Data Sources To Monitor H1N1 Vaccine Safety Points To  Potential For Even Broader Safety Surveillance. Health Aff (Millwood). 2012 Nov; 31(11):2518-2527.

208. Santry C. Health workers in British Columbia must be vaccinated against flu  or wear a mask, new policy says. BMJ. 2012 Nov 20; 345:e7860.

209. Schaefer Ziemer K, Hoffman MA. Beliefs and attitudes regarding human papillomavirus vaccination among college-age women. J Health Psychol. 2012 Nov 26. [Epub ahead of print].

210. Scherpenisse M, Mollers M, Schepp RM, Meijer CJ, de Melker HE, Berbers GA, van der Klis FR. Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination. Hum Vaccin Immunother. 2012 Nov 13; 9(2). [Epub ahead of print].

211. Schindler M, Blanchard-Rohner G, Meier S, Martinez de Tejada B, Siegrist CA, Burton-Jeangros C. Vaccination against seasonal flu in Switzerland: The indecision of pregnant women encouraged by healthcare professionals. Rev Epidemiol Sante Publique. 2012 Nov 7. [Epub ahead of print].

212. Schmader KE, Oxman MN, Levin MJ, Johnson G, Zhang JH, Betts R, Morrison VA,  Gelb L, Guatelli JC, Harbecke R, Pachucki C, Keay S, Menzies B, Griffin MR, Kauffman C, Marques A, Toney J, Keller PM, Li X, Chan IS, Annunziato P; for the Shingles Prevention Study Group. Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012 Nov; 55(10):1320-1328.

213. Schure RM, Hendrikx LH, de Rond LG, Oztürk K, Sanders EA, Berbers GA, Buisman AM. T-Cell Responses before and after the Fifth Consecutive Acellular Pertussis Vaccination in 4-Year-Old Dutch Children. Clin Vaccine Immunol. 2012 Nov;19(11):1879-86.

214. Schwarz TF, Schmoele-Thoma B. Assessment of functional antibacterial opsonophagocytic antibodies elicited by 13-valent pneumococcal conjugate vaccine  administered concomitantly with trivalent influenza vaccine in a randomized clinical trial in adults aged ≥65 years. Vaccine. 2012 Nov 1. [Epub ahead of print].

215. Schönberger K, Ludwig MS, Wildner M, Kalies H. Timely MMR Vaccination in Infancy: Influence of Attitudes and Medical Advice on the Willingness to Vaccinate. Klin Padiatr. 2012 Nov; 224(7):437-442.

216. Seale H, Trung L, Mackie FE, Kennedy SE, Boros C, Marshall H, Tidswell J, Shaw PJ, Montgomery K, Macintyre CR. A qualitative study investigating knowledge  and attitudes regarding human papillomavirus (HPV) and the HPV vaccine among parents of immunosuppressed children. Vaccine. 2012 Nov 19; 30(49):7027-31.

217. Sealy R, Webby RJ, Crumpton JC, Hurwitz JL. Differential localization and function of antibody-forming cells responsive to inactivated or live-attenuated influenza virus vaccines. Int Immunol. 2012 Nov 8. [Epub ahead of print].

218. Seiberling M, Bologa M, Brookes R, Ochs M, Go K, Neveu D, Kamtchoua T, Lashley P, Yuan T, Gurunathan S. Safety and immunogenicity of a pneumococcal histidine triad protein D vaccine candidate in adults. Vaccine. 2012 Dec 14; 30(52):7455-60.

219. Serinken M, Gozlukaya A, Sari I, Karcioglu O. Thrombocytopenia after Tetanus Prophylaxis with Tetanus-Diphtheria (Td) Vaccine. J Emerg Med. 2012 Nov 7. [Epub ahead of print].

220. Shaikh MF, Baqai TJ, Tahir H. Acute brachial neuritis following influenza vaccination. BMJ Case Rep. 2012 Nov 28; 2012.

221. Shapiro ED. Acellular vaccines and resurgence of pertussis. JAMA. 2012 Nov 28; 308(20):2149-50.

222. Shaw AR. Human Papillomavirus Vaccines Six Years After Approval. Annu Rev Med. 2012 Nov 19. [Epub ahead of print].

223. Shen AK, Bridges CB, Tan L. The first national adult immunization summit 2012: Implementing change through action. Vaccine. 2012 Nov 19. [Epub ahead of print]. 

224. Sheridan SL, Ware RS, Grimwood K, Lambert SB. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a north american outbreak. Clin Infect Dis. 2012 Nov; 55(10):1434-5.

225. Shinoki T, Hara R, Kaneko U, Miyamae T, Imagawa T, Mori M, Yokota S. Safety  and response to influenza vaccine in patients with systemic-onset juvenile idiopathic arthritis receiving tocilizumab. Mod Rheumatol. 2012 Nov; 22(6):871-6.  

226. Sikora JM, Tankersley MS. Adult immunizations: updates and practical guidance for the practicing allergist-immunologist. Ann Allergy Asthma Immunol. 2012 Nov; 109(5):295-302.

227. Singh A, Pallikadavath S, Ogollah R, Stones W. Maternal tetanus toxoid vaccination and neonatal mortality in rural north India. PLoS One. 2012; 7(11):e48891.

228. Soares-Weiser K, Maclehose H, Bergman H, Ben-Aharon I, Nagpal S, Goldberg E, Pitan F, Cunliffe N. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008521.

229. Sood N, Wagner Z. For-profit sector immunization service provision: does low provision create a barrier to take-up? Health Policy Plan. 2012 Nov 9. [Epub ahead of print].

230. Starr M. Paediatric Travel Medicine: vaccines and medications. Br J Clin Pharmacol. 2012 Nov 16. [Epub ahead of print].

231. Sudarshan S, Huang EH, Lim PL, Leo YS, Lim SA. A case of post-vaccination optic neuritis: coincidence or causative? Eye (Lond). 2012 Nov; 26(11):1498.

232. Tanimoto T, Murashige N, Hosoda M, Kusumi E, Ono S, Kami M, Shibuya K. Vaccination for whom? Time to reinvigorate Japanese vaccine policy. Lancet. 2012  Nov 10;380(9854):1647.

233. Temte JL. The vaccine connection. Vaccine. 2012 Nov 26;30(50):7144.

234. The RTS,S Clinical Trials Partnership. A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants. N Engl J Med. 2012 Nov 9. [Epub ahead of print].

235. Thomas TL, Strickland OL, Diclemente R, Higgins M, Haber M. Rural African American Parents' Knowledge and Decisions About Human Papillomavirus Vaccination. J Nurs Scholarsh. 2012 Nov 5. [Epub ahead  of print].

236. Thomassen YE, van 't Oever AG, Vinke M, Spiekstra A, Wijffels RH, van der Pol LA, Bakker WA. Scale-down of the inactivated polio vaccine production process. Biotechnol Bioeng. 2012 Nov 28. [Epub ahead of print].

237. Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J. Quadrivalent Ann Arbor strain live attenuated influenza vaccine. Expert Rev Vaccines. 2012 Nov 14. [Epub ahead of print].

238. Tomljenovic L, Shaw CA. No autoimmune safety signal after vaccination with quadrivalent HPV vaccine Gardasil? J Intern Med. 2012 Nov; 272(5):514-5.

239. Tseng HF, Sy LS, Qian L, Marcy SM, Jackson LA, Glanz J, Nordin J, Baxter R,  Naleway A, Donahue J, Weintraub E, Jacobsen SJ; for the Vaccine Safety Datalink (VSD) Team. Safety of a Tetanus-Diphtheria-Acellular Pertussis Vaccine When Used  Off-Label in an Elderly Population. Clin Infect Dis. 2012 Nov 28. [Epub ahead of print].

240. van den Bergh MR, Spijkerman J, Swinnen KM, François NA, Pascal TG, Borys D, Schuerman L, Ijzerman EP, Bruin JP, van der Ende A, Veenhoven RH, Sanders EA. Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein  D-Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial. Clin Infect Dis. 2012 Nov 19. [Epub ahead of print].

241. van Deursen AM, van Mens SP, Sanders EA, Vlaminckx BJ, de Melker HE, Schouls LM, de Greeff SC, van der Ende A; on behalf of the Invasive Pneumococcal Disease  Sentinel Surveillance Laboratory Group. Invasive Pneumococcal Disease and 7-Valent Pneumococcal Conjugate Vaccine, the Netherlands. Emerg Infect Dis. 2012  Nov;18(11).

242. Vuong CD, Hoang PM, Nguyen HL, Nguyen HT, Nguyen TC, Le TT, Dennis DT, Kapella BK, Kile JC, Le MQ. The genetic match between vaccine strains and circulating seasonal influenza A viruses in Vietnam, 2001-2009. Influenza Other Respi Viruses. 2012 Nov 8. doi: 10.1111/irv.12038. [Epub ahead of print].

243. Wall GC, Van Der Veer JJ, Romine MJ, Yeager SM. Assessment of candidacy for  pneumococcal vaccination in intensive care patients. Intensive Crit Care Nurs. 2012 Nov 29. [Epub ahead of print].

244. Wang IK, Lin CL, Chang YC, Lin PC, Liang CC, Liu YL, Chang CT, Yen TH, Huang CC, Sung FC. Effectiveness of influenza vaccination in elderly diabetic patients: A retrospective cohort study. Vaccine. 2012 Nov 12. [Epub ahead of print].

245. Wang L, Lei D, Zhang S. Acellular pertussis vaccines in China. Vaccine. 2012 Nov 26; 30(50):7174-8.

246. Wang S, Chen J, Zhang Y, Diao N, Zhang S, Wu J, Lu C, Wang F, Gao Y, Shao L, Jin J, Weng X, Zhang W. Mycobacterium tuberculosis RD2 and RD11 antigens Rv1985c  and Rv3425 have the promising potential to distinguish active tuberculosis patients from BCG vaccinated individuals. Clin Vaccine Immunol. 2012 Nov 7. [Epub ahead of print].

247. Wheldon CW, Buhi ER, Daley EM. Gay and bisexual men's human papillomavirus vaccine intentions: A theory-based structural equation analysis. J Health Psychol. 2012 Nov 5. [Epub ahead of print].

248. Whitney CG. More evidence for use of pneumococcal conjugate vaccines. Lancet. 2012 Nov 15. [Epub ahead of print].

249. Wilson R, Brown DR, Boothe MA, Harris CE. Knowledge and Acceptability of the HPV Vaccine Among Ethnically Diverse Black Women. J Immigr Minor Health. 2012 Nov 30. [Epub ahead of print].

250. Wooten KG, Wortley PM, Singleton JA, Euler GL. Perceptions matter: Beliefs about influenza vaccine and vaccination behavior among elderly white, black and Hispanic Americans. Vaccine. 2012 Nov 6; 30(48):6927-34.

251. Yang P, Zhang L, Shi W, Lu G, Cui S, Peng X, Zhang D, Liu Y, Liang H, Pang X, Wang Q. Seroprevalence of pandemic (H1N1) 2009 influenza and effectiveness of  2010/2011 influenza vaccine during 2010/2011 season in Beijing, China. Influenza  Other Respi Viruses. 2012 Nov; 6(6):381-8.

252. Yu H, Yang W, Varma JK. To Save Children's Lives, China Should Adopt An Initiative To Speed Introduction Of Pneumonia Vaccines. Health Aff (Millwood). 2012 Nov; 31(11):2545-53.

253. Zapata Sampedro MA. [Effect of prophylactic paracetamol administration at vaccination on infant febrile reaction rates and immune response.]. Enferm Clin.  2012 Nov 28. [Epub  ahead of print].

254. Zehrung D, Jarrahian C, Wales A. Intradermal delivery for vaccine dose sparing: Overview of current issues. Vaccine. 2012 Nov 20. [Epub ahead of print].

255. Zhu FC, Wang JZ, Li XL, Liang ZL, Ge HM, Meng FY, Mao QY, Zhang YT, Zhang ZY, Ji H, Gao F, Guo HJ, Zhu QY, Chu K, Wu X, Li JX, Chen QH, Chen XQ, Zhang WW,  Hu YM, Li L, Li FX, Yao X, Liu P, Wang H, Shen XL. Reactogenicity and immunogenicity of an enterovirus 71 vaccine in chinese healthy children and infants. Pediatr Infect Dis J. 2012 Nov; 31(11):1158-65.

256. Škovránková J, Petráš M. Persistence of humoral immunity to tetanus and diphtheria in hematopoietic stem cell transplant recipients after post-transplant immunization. Pediatr Blood Cancer. 2012 Nov; 59(5):908-13.

[top]